Works matching IS 1007385X AND DT 2022 AND VI 29 AND IP 11

Results: 16

Practice of integrated teaching model based on the concept of PBL in the construction of special topics in cancer biotherapy.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1054, doi. 10.3872/j.issn.1007-385x.2022.11.018
Publication type:: Article

Application of tumor-targeting bacteria in the treatment of immunotherapy: from basic to clinical.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1049, doi. 10.3872/j.issn.1007-385x.2022.11.017
Publication type:: Article

Expression, function and possible mechanism of lncRNA LINC00504 in breast cancer tissues and cells.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1045, doi. 10.3872/j.issn.1007-385x.2022.11.016
Publication type:: Article

Expression, function and clinical significance of MELK in pancreatic cancer.

Published in:

Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1038, doi. 10.3872/j.issn.1007-385x.2022.11.015

By:

JIANG Wenkai;
DU Yan;
ZHOU Yongjie;
ZHOU Wence

Publication type:

Article

Cystathionine β-synthase affects the proliferation of lung adenocarcinoma A549 cells through the AKT/cyclin D1 pathway.

Published in:

Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1032, doi. 10.3872/j.issn.1007-385x.2022.11.014

By:

OUYANG Yunjie;
CAO Peiguo;
ZHANG Xi

Publication type:

Article

Mechanism of transcription factor SP1 affecting drug resistance of small cell lung cancer H446/DDP cells by regulating ABCC1.

Published in:

Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1025, doi. 10.3872/j.issn.1007-385x.2022.11.013

By:

GAO Yuejuan;
LI Zhiping;
HE Feifei;
WANG Jialiang

Publication type:

Article

Severe immune-related hepatitis characterized by elevated bilirubin induced by combination therapy with IBI310 and sintilimab in melanoma patient: a case report and literature review.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1021, doi. 10.3872/j.issn.1007-385x.2022.11.012
Publication type:: Article

Report of one case of immune-related encephalitis caused by malignant pleural mesothelioma treated with nivolumab in combination with ipilimumab and literature review.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1017, doi. 10.3872/j.issn.1007-385x.2022.11.011
Publication type:: Article

Severe immune-related myocarditis induced by combination therapy with sintilimab and IBI310 in malignant melanoma: a case report and literature analysis.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1013, doi. 10.3872/j.issn.1007-385x.2022.11.010
Publication type:: Article

Immune checkpoint inhibitor-related cirrhotic hepatotoxicity: A case report and literature review.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1010, doi. 10.3872/j.issn.1007-385x.2022.11.009
Publication type:: Article

Immune-associated toxic epidermal necrolysis: a case report and literature review.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1006, doi. 10.3872/j.issn.1007-385x.2022.11.008
Publication type:: Article

Immune checkpoint inhibitor-associated uveitis: two case reports and literature review.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 1002, doi. 10.3872/j.issn.1007-385x.2022.11.007
Publication type:: Article

Characteristics and risk factors of immune-related adverse events and pneumonitis associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer.

Published in:

Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 995, doi. 10.3872/j.issn.1007-385x.2022.11.006

By:

WANG Jingyuan;
SUN Hu;
FENG Huijing;
YANG Xiaoling;
ZHANG Junping;
XU Huiru

Publication type:

Article

Research progresses on adverse events of immune checkpoint inhibitors.

Published in:: Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 989, doi. 10.3872/j.issn.1007-385x.2022.11.005
Publication type:: Article

Multidisciplinary management on broad-spectrum toxicity and severe toxicity caused by immune checkpoint inhibitors.

Published in:

Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 978, doi. 10.3872/j.issn.1007-385x.2022.11.003

By:

XU Huiru;
ZHANG Junping

Publication type:

Article

Immune-related adverse events and management strategies of immune checkpoint inhibitor in the treatment of mela.

Published in:

Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 11, p. 971, doi. 10.3872/j.issn.1007-385x.2022.11.002

By:

YANG Yue;
SI Lu;
GUO Jun

Publication type:

Article